All voting VRBPAC members have recommended a monovalent JN.1 lineage vaccine for the 2025-2026 formulation; This does not mean that JN.1 itself will be the spike in the vaccine- JN.1 lineage includes many subvariants including LP.8.1 etc. VRBPAC is discussing which one would be best now.